DaVita Inc. (DVA)
| Market Cap | 11.20B |
| Revenue (ttm) | 11.55B |
| Net Income (ttm) | 773.64M |
| Shares Out | 119.80M |
| EPS (ttm) | 6.31 |
| PE Ratio | 16.19 |
| Forward PE | 12.50 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $102.19 |
| Previous Close | $102.89 |
| Change ($) | -0.70 |
| Change (%) | -0.68% |
| Day's Open | 103.17 |
| Day's Range | 101.23 - 103.87 |
| Day's Volume | 537,425 |
| 52-Week Range | 62.20 - 125.28 |
Francis Chou (Trades, Portfolio), manager of Chou Associates Management, disclosed last week that his firm's top four sells during the fourth quarter of 2020 included the closure of its positi...
Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.
DaVita's (DVA) bottomline in Q4 declines year over year.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -9.73% and -1.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...
Shares of DaVita (NYSE:DVA) decreased after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 10.22% year over year to $1.67, which missed the est...
BOSTON, Feb. 6, 2021 /PRNewswire/ -- Kyros Law Offices is alerting investors of Davita Inc (NYSE:DVA) that the deadline in filing claims from the investor lawsuit settlement against the compan...
Solid performance by net dialysis and the related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the fourth quarter.
DENVER, Jan. 29, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 11, 2021,...
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
DaVita Inc. (NYSE: DVA) is focused on dialysis, which means that it is unlikely to get much of a boost from a reacceleration in volumes within health care, of which Tenet Healthcare Corp (NYSE...
Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
DENVER, Dec. 22, 2020 /PRNewswire/ -- Today, DaVita Kidney Care announced that more than 100,000 DaVita patients have received a kidney transplant since 2000. This milestone represents the cul...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Some reasonably cheap stocks are growth stocks in disguise. If you're looking for undervalued stocks, these 10 are about to take off.
As uncertainty continues and growth stocks remain richly priced, these 10 value stocks could be your ticket to gains in 2021. The post The 10 Most Reliable Value Stocks to Buy for 2021 appeare...
Markets rose on Thursday after jobless claims from last week came in at much better than expected figures. For investors looking to make the most of this market, our deep learning algorithms h...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Is DaVita (DVA) a great pick from the value investor's perspective right now? Read on to know more.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
As of late, it has definitely been a great time to be an investor in DaVita (DVA).
DENVER, Nov. 23, 2020 /PRNewswire/ -- DaVita Inc. today announced its annual cycling event, Tour DaVita, raised nearly $1 million to benefit Bridge of Life, a nonprofit founded by DaVita that ...
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Is (DVA) Outperforming Other Medical Stocks This Year?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
SACRAMENTO, Calif., Nov. 4, 2020 /PRNewswire/ -- DaVita Kidney Care, a leading provider of kidney care services in the United States, issued the following statement: "We are grateful that Cali...
Davita Healthcare Partners sees its Relative Strength Rating move into the 80-plus level. The post Davita Healthcare Partners Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on ...
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Rise in coronavirus cases and uncertainties revolving around the election might keep markets volatile for some time. Here are five stocks to invest in and play safe.
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
DaVita, Inc. (DVA) CEO Javier Rodriguez on Q3 2020 Results - Earnings Call Transcript
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 20.81% and -0.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...
DENVER, Oct. 29, 2020 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the third quarter ended September 30, 2020. During the quarter, notwithstanding the ...
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (DVA) Outperforming Other Medical Stocks This Year?
DENVER, Oct. 22, 2020 /PRNewswire/ -- DaVita Clinical Research (DCR) will present 14 research abstracts from company representatives and medical professionals at the American Society of Nephro...
Many Warren Buffett stocks remain buys.
DENVER, Oct. 15, 2020 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2020, a...
DaVita HealthCare (DVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Grab these four stocks that continue to show tremendous promise despite market volatility resulting from the coronavirus pandemic.
DaVita's business model is able to provide the company with very reliable and stable revenues, as patients need their dialysis treatment on a constant basis.
These three MedTech stocks are expected to grow post their Q3 earnings release.
About DVA
DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In ad... [Read more...]
| Industry Medical Care Facilities | IPO Date Oct 31, 1995 |
| CEO Javier Rodriguez | Employees 67,000 |
| Stock Exchange NYSE | Ticker Symbol DVA |
Financial Performance
In 2020, DaVita's revenue was $11.55 billion, an increase of 1.42% compared to the previous year's $11.39 billion. Earnings were $773.64 million, a decrease of -4.60%.
Analyst Forecasts
According to 12 analysts, the average rating for DaVita stock is "Hold." The 12-month stock price forecast is 120.75, which is an increase of 18.16% from the latest price.